5 Key Takeaways

• 1

  Small molecules retain advantages in oral administration, which can reduce treatment burden and support convenient long-term use.

• 2

  Their ability to cross the blood-brain barrier and reach intracellular targets makes small molecules useful for central nervous system and intracellular therapies.

• 3

  Advances in medicinal chemistry and structure-based design have improved small-molecule potency and selectivity, while computational methods support optimization.

• 4

  Protein degraders are extending small-molecule approaches to targets previously considered undruggable; Ascentage Pharma is advancing a BTK degrader into global phase 1 trials.

• 5

  Small molecules generally offer scalable manufacturing and broad accessibility, and their use is expanding beyond traditional rule-of-five property limits.